Add Siemens to the list of European companies planning to restructuretheir medical divisions. The German vendor announced this monththat it intends to retool its Medical Engineering Group to cometo grips with changes in healthcare in two major markets,
Add Siemens to the list of European companies planning to restructuretheir medical divisions. The German vendor announced this monththat it intends to retool its Medical Engineering Group to cometo grips with changes in healthcare in two major markets, theU.S. and Germany.
The announcement came as Siemens released year-end financialresults that indicated that the company enjoyed a healthy fiscal1996, with both revenues and profits up. Siemens warned, however,that it expected net income to be flat in 1997 due to decliningearnings in the firm's components segment, as well as an expectedrestructuring in the Medical Engineering Group.
"Earnings in the Medical Engineering Group were affectedby ongoing cost-cutting measures in the healthcare industry, particularlyin Germany and the U.S., and by sharply eroding prices,"the company said. "Additional productivity-enhancing measurescouldn't compensate for these factors."
Siemens has not yet released details on how it will restructurethe Medical Engineering Group, although it may give more informationat the upcoming Radiological Society of North America meeting,according to a spokesperson for the vendor's Siemens Medical SystemsU.S. subsidiary in Iselin, NJ.
For the year, Siemens reported revenues of 94.2 billion deutschemarks ($62.08 billion), up 6% compared with 88.8 billion DM ($58.52billion) in 1995. Net income before extraordinary items stoodat 2.49 billion DM ($1.64 billion), compared with net income of2.08 billion DM ($1.37 billion).
The medical group reported sales of 7.1 billion DM ($4.68 billion),up 4% compared with revenues of 6.8 billion DM ($4.48 billion)in fiscal 1995.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.